Abstract

This is a Program Project Application for three years of support to establish a Center for the Study of Neurodegenerative Diseases at the University of Virginia. The Program will be directed by James P. Bennett, Jr., M.D., Ph.D. and will be based in the Department of Neurology. The application is composed of five individual projects and two cores, has a broad scientific base, and has arisen from the evolving collaborative efforts over time of the investigators. Four neurologist and one neurosurgeon clinician-investigators and four basic neuroscientists will pursue projects that will characterize the control of neurotrophic factor metabolism, potential transsynaptic and neuroimmunological etiologies of neurodegenerative diseases (NDD), neuroplastic adaptations in animal models of human NDD, and the biological basis for improved pharmacologic and transplantation therapies of NDD. All projects will be supported by an administration core and a Molecular and Cellular Anatomy core laboratory. Synergistic interactions among the investigators will be encouraged by quarterly meetings and regular annual review by outside consultants.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
1P01NS030024-01
Application #
3100379
Study Section
Neurological Disorders Program Project Review B Committee (NSPB)
Project Start
1992-01-15
Project End
1994-12-31
Budget Start
1992-01-15
Budget End
1992-12-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
University of Virginia
Department
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904

  Publications

Harrison, M B; Kumar, S; Hubbard, C A et al. (2001) Early changes in neuropeptide mRNA expression in the striatum following reserpine treatment. Exp Neurol 167:321-8
Smith, T S; Trimmer, P A; Khan, S M et al. (1997) Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment. Brain Res 765:189-97
Smith, T S; Bennett Jr, J P (1997) Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions. Brain Res 765:183-8
Creedon, D J; Tuttle, J B (1997) Synergistic increase in nerve growth factor secretion by cultured vascular smooth muscle cells treated with injury-related growth factors. J Neurosci Res 47:277-86
Miller, P J; Zaborszky, L (1997) 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease. Exp Neurol 146:212-29
Jung, A B; Bennett Jr, J P (1996) Development of striatal dopaminergic function. I. Pre- and postnatal development of mRNAs and binding sites for striatal D1 (D1a) and D2 (D2a) receptors. Brain Res Dev Brain Res 94:109-20
Gaykema, R P; Zaborszky, L (1996) Direct catecholaminergic-cholinergic interactions in the basal forebrain. II. Substantia nigra-ventral tegmental area projections to cholinergic neurons. J Comp Neurol 374:555-77
Zaborszky, L; Cullinan, W E (1996) Direct catecholaminergic-cholinergic interactions in the basal forebrain. I. Dopamine-beta-hydroxylase- and tyrosine hydroxylase input to cholinergic neurons. J Comp Neurol 374:535-54
Jung, A B; Bennett Jr, J P (1996) Development of striatal dopaminergic function. III: Pre- and postnatal development of striatal and cortical mRNAs for the neurotrophin receptors trkBTK+ and trkC and their regulation by synaptic dopamine. Brain Res Dev Brain Res 94:133-43
Harrison, M B; Tissot, M; Wiley, R G (1996) Expression of m1 and m4 muscarinic receptor mRNA in the striatum following a selective lesion of striatonigral neurons. Brain Res 734:323-6

Showing the most recent 10 out of 32 publications